<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916382</url>
  </required_header>
  <id_info>
    <org_study_id>SONIA 2</org_study_id>
    <nct_id>NCT01916382</nct_id>
  </id_info>
  <brief_title>Suitability of Nitisinone in Alkaptonuria 2</brief_title>
  <acronym>SONIA 2</acronym>
  <official_title>An International, Multicentre, Randomised, Evaluator-blind, No-treatment Controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Nitisinone in Patients With Alkaptonuria After 12 Months of Treatment, Followed by an Additional 36 Month Treatment Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proposal to develop the orphan designated drug, nitisinone, for the treatment of a
      rare Mendelian disease, Alkaptonuria (AKU). Thanks to our existing successful fundamental and
      clinical research (cell models, animal models, natural history studies), we are now ready for
      this final stage of clinical development of nitisinone for AKU: a phase 3 clinical trial to
      prove efficacy. The results of DevelopAKUre will allow us to make the case to the European
      Medicines Agency for marketing authorisation of nitisinone for AKU, thereby contributing to
      the goal of the International Rare Diseases Research Consortium of developing 200 new
      therapies by 2020.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 houre Urine Homogentisic acid</measure>
    <time_frame>year 1</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Alkaptonuria</condition>
  <arm_group>
    <arm_group_label>Nitisinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Homogentisic acid lowering drug intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>comparrator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone</intervention_name>
    <description>drug</description>
    <arm_group_label>Nitisinone</arm_group_label>
    <other_name>Orfadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A patient must fulfil the following criteria in order to be included in the study:

        1. Diagnosis of AKU Any Clinical manifestations of AKU, such as clinical ochronosis or
        chronic back/joint pain.

        3. Age â‰¥25 years. 4. Willing and able to visit the investigational site for study visits.
        5. Signed written informed consent given.

        Exclusion Criteria:

        The presence of any of the following will exclude a patient from inclusion in the study:

          1. Currently pregnant or lactating.

          2. Female patient of child-bearing potential not using a reliable method of
             contraception.

          3. Known allergy to nitisinone or any of the constituents of the investigational product.

          4. Current malignancy.

          5. Uncontrolled hypertension (blood pressure greater than 180 mmHg systolic or greater
             than 95 mmHg diastolic).

          6. Unstable cardiovascular disease.

          7. Serum potassium &lt; 3.0 mmol/L.

          8. eGFR &lt; 60 mL/min .

          9. ALT &gt; 1.5 x upper limit of normal.

         10. Haemoglobin &lt; 10.0 g/dL.

         11. Platelets &lt; 100 x 109/L.

         12. Total white blood count &lt; 3.0 x 109/L or neutrophil count &lt; 1.5 x 109/L.

         13. History of alcohol or drug abuse.

         14. Participation in another clinical study within 3 months of randomization.

         15. Treatment with nitisinone within 60 days of randomization.

         16. Psychiatric or somatic illness that interferes with compliance or communication with
             health care personnel.

         17. Foreseeable inability to cooperate with given instructions or study procedures.

         18. Any other medical condition which in the opinion of the investigator makes the patient
             unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L Ranganath</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Liverpool and Broadgreen University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Professor Lakshminarayan Ranganath</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alkaptonuria, nitisinone,Ochronosis, Homogentisic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alkaptonuria</mesh_term>
    <mesh_term>Ochronosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

